F2G has discovered and is developing the orotomides, a novel class of antifungal agents. The orotomides act via a different mechanism than currently marketed antifungal agents and are active against ...

F2G’s attempt to end a two-decade drought in novel therapies for invasive fungal infections has hit a hurdle after the FDA said it was unable to approve its olorofim candidate. The US regulator sent a ...

MANCHESTER, United Kingdom, Oct. 21, 2022 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening ...

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization. The Cowen Healthcare Investments-led round comes four years ...

After F2G’s first attempt to get a brand-new class of antifungal to market was derailed by the FDA, the U.K.-based biotech has secured $100 million in fresh funding to bankroll another push towards ...

PRINCETON, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- F2G Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for olorofim for the ...

Sept 12 (Reuters) - F2G said on Thursday it has raised $100 million from investors including AMR Action Fund, backed by large drugmakers such as Johnson & Johnson and Pfizer, to help it develop ...

- Brings substantial pharmaceutical expertise to lead the development and commercialization of olorofim in the USA - Ian Nicholson stepping down to pursue non-executive roles MANCHESTER, England and ...

MANCHESTER, United Kingdom, June 18, 2025 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company developing olorofim, a novel therapy to treat life-threatening rare fungal infections ...

(Reuters) - F2G said on Thursday it has raised $100 million from investors including AMR Action Fund, backed by large drugmakers such as Johnson & Johnson and Pfizer, to help it develop treatments for ...